The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a study to understand Alzheimer's disease (AD) better. ADNI4 continues the work of previous studies to find biological markers (like genes or proteins) that can help in AD trials. Participants aged 55-90 from 59 sites in the U.S. and Canada will be part of three groups: cognitively normal, mild cognitive impairment (MCI), and dementia. This is a non-treatment study, meaning no medicine or therapy will be given.
Participants will have tests and brain scans (PET and MRI) over up to 5 years. MRI (Magnetic Resonance Imaging) uses magnets and radio waves to take pictures of the brain. PET (Positron Emission Tomography) scans help to see how the brain is working. Participants must have a partner who can help during the study, like attending visits or giving information over the phone.
- Study involves regular tests and scans for up to 5 years.
- No new medicines or treatments will be provided during the study.
- Participants must have a study partner who can support them.
For more information, please visit the ADNI4 Study website.